Listing of Patents. Company shall have the sole right to determine which of the Licensor Patents, if any, shall be listed for inclusion in the Approved Drug Products with Therapeutic Equivalence Evaluations pursuant to 21 U.S.C. Section 355, or any successor Law in the United States, together with any comparable Laws in any other country in the Territory.
Appears in 3 contracts
Samples: License Agreement, License Agreement (BeiGene, Ltd.), License Agreement (BeiGene, Ltd.)
Listing of Patents. Notwithstanding any Licensor Patent prosecution rights of Licensor under this Agreement, Company shall have the sole right to determine which of the Licensor Patents, if any, shall be listed for inclusion in the Approved Drug Products with Therapeutic Equivalence Evaluations pursuant to 21 U.S.C. Section 355, or any successor Law in the United States, together with any comparable Laws in any other country in the Territory.
Appears in 2 contracts
Samples: License Agreement (Liquidia Corp), License Agreement (Liquidia Corp)
Listing of Patents. Company shall have the sole right to determine which of the Licensor Patents, if any, shall be listed for inclusion in the Approved Drug Products with Therapeutic Equivalence Evaluations pursuant to 21 U.S.C. Section 355, or any successor Law in the United States, together with any comparable Laws in any other country in the Company Territory.
Appears in 2 contracts
Samples: License Agreement (BeiGene, Ltd.), License Agreement (BeiGene, Ltd.)
Listing of Patents. Company […***…] shall have the sole right to determine which of the Licensor Patents, if any, shall be listed for inclusion in the Approved Drug Products with Therapeutic Equivalence Evaluations pursuant to 21 U.S.C. Section 355, or any successor Law in the United States, together with any comparable Laws in any other country in the Territory.country. *Confidential Treatment Requested
Appears in 1 contract
Samples: Master License Agreement (Viking Therapeutics, Inc.)
Listing of Patents. Company [***] shall have the sole right to determine which of the Licensor Patents, if any, shall be listed for inclusion in the Approved Drug Products with Therapeutic Equivalence Evaluations pursuant to 21 U.S.C. Section 355, or any successor Law in the United States, together with any comparable Laws in any other country in the Territorycountry.
Appears in 1 contract
Samples: Master License Agreement (Ligand Pharmaceuticals Inc)
